



PROGRAMME

European Workshop for Rheumatology Research
May 5 – 8, 2022 / Vienna, Austria

Lilly



2	Presenting EWRR 2022
3	Committees
6	Meeting Venue and Location
9	General Information
11	Scientific Programme
	11 Programme Overview
	12 Thursday, May 5 (Day 1)
	13 Friday, May 6 (Day 2)
	15 Saturday, May 7 (Day 3)
	18 Posters
36	EULAR Travel Bursaries
37	EULAR Study Group Meetings
39	Sponsors
42	Venue Plan

WELCOME ADDRESS



Günter Steiner

Dear Friends and Colleagues,

We are exceedingly happy to welcome you to the 41st European Workshop for Rheumatology Research which, with a one year's delay, has returned to Vienna after 21 years. In 2021, for the first time in its history, the EWRR had to be cancelled and postponed until May 2022 because the Covid-19 pandemic made it impossible to hold the EWRR at its traditional date in February. Being aware that many meetings scheduled for winter might be postponed until spring we were somewhat concerned that the number of participants would be lower than usual, but this is definitely not the case. We received 160 abstract submissions and have more than 240 participants. Thank you for showing us your continuous and unbowed interest in the EWRR!

The EWRR has a long tradition and is a unique event fostering presentation and discussion of novel findings and is still considered Europe's premier meeting for basic and translational research in the field of rheumatic and musculoskeletal diseases. The meeting will cover a wide spectrum of topics, including innate and adaptive immunity, autoantibodies and other biomarkers, genetics and epigenetics, organ and tissue inflammation, joint degeneration and repair, as well as the impact of Covid-19 on rheumatic diseases. In addition we will touch on recent advances in regenerative and personalised medicine. The EWRR is particularly aimed at attracting young scientists who are given the opportunity to present their work in an informal and interactive environment. In addition to state-of-the-art lectures given by prestigious researchers inside and outside the rheumatology field, there will be short oral presentations of outstanding abstracts and twelve guided poster tours allowing most if not all authors to present their work. This will create valuable opportunities for vivid discussions and scientific networking which may stimulate new ideas and collaborations. To further enhance interactions two networking are planned, a Welcome reception on Thursday and a Farewell party on Saturday. Friday evening is at your disposal allowing you together with old and new friends to explore and appreciate the beauty and hospitality of Vienna.

We hope that you will appreciate our efforts and enjoy this unique scientific event together with us after a break which lasted for more than two years.

Günter Steiner and Daniel Aletaha

On behalf of the EWRR 2022 organising committee



Daniel Aletaha

CONGRESS PRESIDENT

Daniel Aletaha Vienna AUT

CONGRESS CHAIRS

Silvia Hayer Vienna AUT

Günter Steiner Vienna AUT

LOCAL SCIENTIFIC COMMITTEE

Stephan Blüml Vienna AUT

Michael Bonelli Vienna AUT

Leo Heinz Vienna AUT

Thomas Karonitsch Vienna AUT

Hans Kiener Vienna AUT

Helga Radner Vienna AUT

Clemens Scheinecker Vienna AUT

Daniela Sieghart Vienna AUT

Paul Studenic Vienna AUT

INTERNATIONAL SCIENTIFIC COMMITTEE

Florence Apparailly Montpellier FR

Hyun-Dong Chang Berlin GER

Ursula Fearon Dublin IRL

Marije Koenders Nijmegen NL

Gerhard Krönke Erlangen GER

Vivi Malmström Stockholm SWE

Silvia Monteagudo Leuven BEL

Caroline Ospelt Zürich CH

Johan Rönnelid Uppsala SWE

Leonie Taams London UK

René Toes Leiden NL

Lisa van Baarsen Amsterdam NL

INTERNATIONAL ABSTRACT**SELECTION COMMITTEE**

Daniel Aletaha Vienna AUT

Florence Apparailly Montpellier FR

Stephan Blüml Vienna AUT

Michael Bonelli Vienna AUT

Dimitrios Boumpas Athens GR

Aline Bozec Erlangen GER

Gerd Burmester Berlin GER

Hyun-Dong Chang Berlin GER

Andy Cope London UK

Maurizio Cutolo Geneva IT

Dirk Elewaut Gent BEL

Ursula Fearon Dublin IRL

Joao Fonseca Lisbon POR

Silvia Hayer Vienna AUT

Leonhard Heinz Vienna AUT

Tom Huizinga Leiden NL

John Isaacs Newcastle UK

Christian Jorgensen Montpellier FR

Thomas Karonitsch Vienna AUT

Hans Kiener Vienna AUT

Marije Koenders Nijmegen NL

Gerhard Krönke Erlangen GER

Rik Lories Leuven BEL

Vivi Malmström Stockholm SWE

Iain McInnes Glasgow UK

Attila Mocsai Budapest HUN

Silvia Monteagudo Leuven BEL

Ulf Müller-Ladner Bad Nauheim GER

Gyorgy Nagy Budapest HUN

Caroline Ospelt Zurich CH

Thomas Pap Münster GER

Frederique Ponchel Leeds UK

Johan Rönnelid Uppsala SWE

Jean Roudier Marseille FR

Clemens Scheinecker Vienna AUT

Daniela Sieghart Vienna AUT

Karl Skriner Berlin GER

Günter Steiner Vienna AUT

Paul Studenic Vienna AUT

Zoltan Szekanecz Debrecen HUN

Leonie Taams Newcastle UK

René Toes Leiden NL

Lisa van Baarsen Amsterdam NL

Diane van der Woude Leiden NL

FOR A LIFE THAT'S NON-STOP^{1,2*}



**UNQUESTIONABLE
JOINT EFFICACY¹**



**PROVEN
DURABILITY³**



**COMPLETE SKIN
CLEARANCE^{1*}**

Lasting, consistent relief^{3**}

DISCOVER-1 & -2: HAQ-DI least squares mean change at week 24 (q8w): -0.32 & -0.37 respectively (REF 1, 2). * DISCOVER-2: PASI90 response at week 24 (q8w) vs. placebo: 69% vs. 10% (p<0.0001); IGA response 0/1 at week 24 (q8w) vs. placebo: 70% vs 19% (p<0.0001) (Ref 1). ** DISCOVER-2: 75% of Patients (q8w) achieved ARC20 at week 24, 74% at week 100 (NR) (Ref 3).

1. Mease PJ, et al. Lancet 2020;395:1126-1136. 2. Deodhar A et al. Lancet 2020;395:1115-1125. 3. McInnes IB, et al. Arthritis Rheumatol 2021;doi.org/10.1002/art.42010.

TREMFYA® ABBREVIATED PRESCRIBING INFORMATION BASED ON THE EU SUMMARY OF PRODUCT CHARACTERISTICS: Name of medicinal product: Tremfya® 100 mg solution for injection in pre-filled syringe, Tremfya® 100 mg solution for injection in pre-filled pen. **Qualitativ:** Each pre-filled syringe contains 100 mg of guselkumab in 1 mL solution. Each pre-filled pen contains 100 mg of guselkumab in 1 mL solution. Guselkumab is a fully human immunoglobulin G1 lamda (IgG1 λ) monoclonal antibody (mAb) to the interleukin (IL)-23 protein, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. **List of excipients:** Histidine, Histidine monohydrochloride monohydrate, Polysorbate 80, Sucrose, Water for injections. **Therapeutic indications:** Plaque psoriasis: Tremfya® is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Psoriatic arthritis Tremfya®, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy. **Contraindications:** Serious hypersensitivity to the active substance or to any of the excipients listed. Clinically important active infections (e.g., active tuberculosis). **Marketing authorization holder:** Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Belgium. **Distribution in Austria:** JANSSEN-CILAG Pharma GmbH, Vergartenstraße 206B, A-1020 Vienna. **Conditions or restrictions regarding supply and use:** Medicinal product subject to restricted medical prescription. **ATC-Code:** L04AC16. Refer to SmPC for further warnings, contraindications, dosing instructions, other undesirable effects and instructions regarding pregnancy and lactation. AT_CP-307382_29Mar2022

INTERNATIONAL ADVISORY BOARD

Dimitrios Boumpas	Athens	GR
Chris Buckley	Oxford	UK
Gerd Burmester	Berlin	GER
Andrew Cope	London	UK
Maurizio Cutolo	Genova	IT
Niek de Vries	Amsterdam	NL
Oliver Distler	Zurich	CH
Dirk Elewaut	Gent	BEL
Joao Fonseca	Lisbon	POR
Cem Gabay	Geneva	CH
Tom Huizinga	Leiden	NL
John Isaacs	Newcastle	UK
Christian Jorgensen	Montpellier	FR
Marije Koenders	Nijmegen	NL
Rik Lories	Leuven	BEL
Ingrid Lundberg	Stockholm	SWE
Wlodzimirz Maslinski	Warsaw	PL
Marco Matucci-Cerinic	Florence	IT
Iain McInnes	Glasgow	UK
Pierre Miossec	Lyon	FR
Ulf Müller-Ladner	Bad Nauheim	GER
Gyorgy Nagy	Budapest	HUN
Thomas Pap	Munster	GER
Costantino Pitzalis	London	UK
Frederique Ponchel	Leeds	UK
Andreas Radbruch	Berlin	GER
Jean Roudier	Marseille	FR
Georg Schett	Erlangen	GER
Guy Serre	Toulouse	FR
Zoltan Szekanecz	Debrecen	HUN
Douglas Veale	Dublin	IRL
Jiri Vencovsky	Prague	CZ

HONORARY COMMITTEE

Ferry Breedveld	Leiden	NL
Jean-Michel Dayer	Geneva	CH
Paul Emery	Leeds	UK
Steffen Gay	Zurich	CH
Lars Klareskog	Stockholm	SWE
Frank Luyten	Leuven	BEL
Ravinder Maini	London	UK
Gabriel Panayi	London	UK
Josef Smolen	Vienna	AUT
Leo van de Putte	Nijmegen	NL
Frank Wollheim	Lund	SWE

SCIENTIFIC ORGANISER

Medical University of Vienna
Department of Medicine III
Division of Rheumatology
 Währinger Gürtel 18-20
 1090 Vienna (AUT)

LOCAL WORKSHOP ORGANISER

Wiener Medizinische Akademie GmbH
 Alser Straße 4
 1090 Vienna (AUT)

MEETING VENUE AND LOCATION

Novotel Wien Hauptbahnhof

Canettistraße 6
 1100 Vienna
 Austria
www.novotel-wien-hauptbahnhof.com/en/

HOW TO GET THERE

PUBLIC TRANSPORT


Vienna has an excellent **PUBLIC TRANSPORT SYSTEM**, which is very effective and inexpensive.

You can find all the information related to the public transportation on the [website of the Wiener Linien](#) (Vienna public transport provider). Furthermore, you can download the Wiener Linien's official [WienMobil app](#). WienMobil makes it possible to plan, book and pay for various modes of transport. Wiener Linien tickets can be purchased and displayed directly and easily in the app or purchased at ticket vending machines in all underground stations (maestro debit cards accepted), at news agent's, or at Vienna Transport Authority's ticket offices.

Tickets purchased in advance are cheaper and must be stamped in a blue ticket cancelling machine on the tram or bus, or at the barrier before boarding the underground train.

- **Single trip tickets** can be used for any single trip within Vienna. You may change lines (and switch between bus, tram, underground, or urban train), but you may not interrupt your journey. Ticket price: EUR 2.60 when bought in advance.
- **Day ticket** valid for one day from the start date until 1.00 am on the following day. Price: EUR 5.60
- **The 24-hour pass** is valid throughout Vienna for exactly 24 hours from the time it is stamped. Price: EUR 8.00
- **The 48-hour pass** is valid throughout Vienna for exactly 48 hours from the time it is stamped. Price: EUR 14.10
- **The 72-hour pass** is valid throughout Vienna for exactly 72 hours from the time it is stamped. Price: EUR 17.10

(Please note that quoted prices are subject to change)





ARRIVING BY TRAIN

Vienna has excellent rail connections to all major European cities. The Novotel Wien Hauptbahnhof is just a few steps away from the Vienna Central Station (Hauptbahnhof). Just look for the exit "Canettistrasse" on the street level.

ARRIVING BY AIR

You can choose between the following transfer options when travelling from the airport to the meeting hotel.

The [airport express bus](#) takes around 25 minutes to reach the Vienna Central Station (Hauptbahnhof) Vienna. The [line VAL 1](#) is operating every hour between Vienna Central Station (Hauptbahnhof) to Vienna Airport from 3.30 a.m. to 8.30 p.m. Single ticket approx. 8 EUR, return ticket approx. 13 EUR.

You may also opt for the [standard rail service \(ÖBB\)](#) which takes approx. 15 minutes to the Vienna Central Station (Hauptbahnhof) and is less costly, (Rail Jet RJ) single ticket approx. 4.30 EUR, return ticket approx. 8.60 EUR.

Importantly, use only the express train (Railjet) and not the S-Bahn as the S-Bahn stops at the station Wien-Mitte where you would have to switch to the underground line U3 to Stephansplatz and then switch to the underground line U1 to the Vienna Central Station (Hauptbahnhof) approx. 20 min).

The [City Airport Train \(CAT\)](#) service is another option but less convenient because it will take you only to Station Wien-Mitte, where you need to switch to U1/U3 as described above. Price for a single ticket is 12 EUR plus ticket for the subway. You can of course take a taxi from Wien-Mitte to the Novotel (approx. 10 min).

From the airport you can also reach the Novotel by taxi in 30-40 minutes depending on traffic.

Costs approx. 50 EUR.

ARRIVING BY CAR

If you arrive by car please note that the hotel does not have its own parking garage. You may use the QBC public parking garage with direct access to the hotel and meeting venue. Special rates apply if you have your ticket validated at the hotel reception.

QBC Garage

Karl-Popper-Straße 4, 1100 Vienna

Price per hour: EUR 2.50

Price per day: EUR 25.00

Price only valid after first being validated at the hotel reception.

Payment at the machine in the car park.

ABOUT VIENNA

Austria's capital Vienna has 1.9 million inhabitants and ranks among the most attractive cities worldwide with a high quality of life. Vienna is a dream city for anyone with an interest in history and culture. Narrow medieval alleyways and grand boulevards lead to historic sights such as the Imperial Palace (Hofburg), Belvedere Palace, Burgtheater, the Spanish Riding School, St. Stephen's Cathedral, the Opera House, Karlskirche, or Schönbrunn Palace. In 2001, the city centre was designated a UNESCO World Heritage Site.

Vienna possesses a lively and vast array of cultural attractions from classical or experimental theatre, film or dance festivals, opera or operetta, as well as exhibitions and concerts. The Museum of Fine Arts is one of the world's largest and most distinguished museums housing priceless works of art. For those interested in Jugendstil (Art Nouveau) and/or contemporary art the Museums Quartier (MQ) is the place to go located in close vicinity to the Museum of Fine Arts. Art accompanies you wherever you go in Vienna – even some of its underground stations are listed properties because of their elegant ornamental Jugendstil style designed by Otto Wagner.

Vienna's distinction as a place for scientific research and innovation goes back many centuries, it is one of the oldest university cities in Europe. Today, with 190,000 students, Vienna is the biggest university city in the German-speaking countries. Around a quarter of the city's enrolled students come from abroad. The research landscape is shaped by nine universities, five technical colleges, as well as almost 1,500 research institutions. Life sciences and information technologies are evidence of the dynamic and intense research activities in Vienna's areas of competence. Also, creative industries are a vibrant area of activity where creative products and solutions are developed. Urban technologies developed in Vienna are in high demand globally. In the environmental sector in particular, research is highly successful.

V.A.T.

A value-added tax (V.A.T.) of generally 20 % is applied to most products and services (a 10 % V.A.T. applies on e.g. books, food and a few other items). The V.A.T. is included in the displayed price.

Local Weather

The last month of the spring, May, is a pleasant month in Vienna, Austria, with average temperature ranging between min 12°C and max 21°C .

Rainfall

In May, in Vienna, the rain falls on 8.3 days.





GENERAL INFORMATION

ABSTRACTS

Accepted abstracts will be published online in a password protected area.

INTERNET

Free wireless internet access is available throughout the venue to all participants.

CASH MACHINE

Cash machines are available at Hauptbahnhof in close vicinity to the meeting venue.

MOBILE DEVICES

As a courtesy to all conference attendees and speakers, cellular phones, pagers and other electronic devices must be operated in silent or vibration mode during sessions. No cellular phone conversations are permitted during sessions.

CERTIFICATE OF ATTENDANCE

A certificate of attendance will be sent by email (to the email address provided during the registration process) to all duly registered participants, after the meeting.

MEETING DOCUMENTS AND BADGES

Meeting documents should be collected onsite at the registration desk located on the ground level of the meeting venue. Name badges must be worn visibly at all times during the meeting.

FOOD AND BEVERAGE

Complimentary lunch and coffee/tea breaks and are provided at the meeting venue on all meeting days.

NETWORKING EVENTS

- **Thursday 5 May 2022 | 19:00**
Welcome Reception & Networking Dinner at the Novotel Wien Hauptbahnhof
- **Friday 6 May 2022 |**
Free disposal
- **Saturday 7 May 2022 | 20:00**
Networking & Farewell Dinner Wolke 19 at Ares Tower Donau-City-Straße 11 1220 Vienna



POSTERS & GUIDED POSTER TOURS

All posters will be displayed from Thursday evening to Saturday evening.

- Mounting date: **Thursday 5 May 2022** | from 19:00
- Dismantling date: **Saturday 7 May 2022** | from 18:50

Posters are located in the congress hall and on the conference level (1st floor). Authors of accepted posters are requested to be at their poster during the assigned poster tour in order to present their work (maximum 4 minutes) and enable discussion.

Guided poster tours:

- **Friday 6 May 2022** – Topics 1, 3, 5, 6, 8, 11 12:30 – 14:00
- **Saturday 7 May 2022** – Topics 2, 4, 7, 9, 10, 12 12:30 – 14:00

Adhesive stickers are available in the poster hanging area.

REGISTRATION DESK OPENING HOURS

Thursday 5 May 2022	12:00 – 19:00
Friday 6 May 2022	08:00 – 18:30
Saturday 7 May 2022	08:00 – 19:00

SMOKING POLICY

The entire meeting venue is non-smoking.

SPEAKERS PREVIEW ROOM

Presentations need to be handed to the technician the day before the respective session or can be sent by e-mail to ewrr2022@wma.co.at.

TRAVEL INSURANCE

It is recommended that participants obtain adequate cover for travel, health and accident insurance before they depart from their countries. EWRR and the Wiener Medizinische Akademie GmbH as organisers cannot accept responsibility for personal injuries, or loss of, or damage to, private property belonging to the workshop participants.



PROGRAMME OVERVIEW

Thursday 5 May 2022

13:30 – 15:30	EULAR STUDY GROUPS	Conference Level
16:00 – 16:15	WELCOME AND OPENING REMARKS	Congress Hall
16:15 – 17:45	SESSION 1 – TISSUE HOMEOSTASIS	Congress Hall
17:45 – 18:30	KEYNOTE LECTURE	Congress Hall
19:00	Welcome Reception and Networking Dinner	Conference Level

Friday 6 May 2022

08:30 – 10:00	SESSION 2 – GENES AND BIOMARKERS	Congress Hall
10:00 – 10:30	Coffee break and poster viewing 	Ground Level and Conference Level
10:30 – 12:00	SESSION 3 – EPIGENETICS	Congress Hall
12:00 – 12:30	Lunch Break 	Ground Level and Conference Level
12:30 – 14:00	POSTER PRESENTATIONS AND GUIDED POSTER TOURS	Conference Level
14:00 – 15:30	SESSION 4 – INNATE IMMUNE CELLS	Congress Hall
15:30 – 16:00	Coffee break and poster viewing 	Ground Level and Conference Level
16:00 – 17:30	SESSION 5 – REGENERATIVE MEDICINE AND SENESCENCE	Congress Hall
17:30 – 18:15	KEYNOTE LECTURE	Congress Hall

Saturday 7 May 2022

08:30 – 10:00	SESSION 6 – B CELLS AND T CELLS	Congress Hall
10:00 – 10:30	Coffee break and poster viewing 	Ground Level and Conference Level
10:30 – 12:00	SESSION 7 – ORGAN AND TISSUE INFLAMMATION	Congress Hall
12:00 – 12:30	Lunch Break 	Ground Level and Conference Level
12:30 – 14:00	POSTER PRESENTATIONS AND GUIDED POSTER TOURS	Conference Level
12:30 – 14:00	International Advisory Board Meeting	Room Create
14:00 – 15:30	SESSION 8 – JOINT DEGENERATION AND REPAIR	Congress Hall
15:30 – 16:00	Coffee break and poster viewing 	Ground Level and Conference Level
16:00 – 17:30	SESSION 9 – PRECISION MEDICINE AND NOVEL TARGETS	Congress Hall
17:30 – 18:15	KEYNOTE LECTURE	Congress Hall
18:15 – 18:30	AWARD CEREMONY – EULAR abstract prizes	Congress Hall
18:30 – 18:45	EWRR 2023 – A glimpse of Dublin	Congress Hall
18:45 – 18:50	Closing Remarks	Congress Hall
20:00	Networking Event and Farewell Dinner	at Wolke 19

Thursday, May 5, 2022 (Day 1)

13:00 - 18:00 Registration**13:30 - 15:30 EULAR study groups (For details see page 37)**

- European Consensus Finding Study Group on Laboratory Investigation in Rheumatology (*ECFSG*)
Room: Texas Eagle (*1st floor*)
- Gene & Cell Therapy Study Group (*GCTSG*)
Room: Orient Express (*1st floor*)
- Study Group on Osteoarthritis (*SGOA*)
Room: Trans Siberian (*1st floor*)

16:00 - 16:15 WELCOME AND OPENING REMARKS**16:15 - 17:45 SESSION 1 - TISSUE HOMEOSTASIS****Chair:** Ursula Fearon (*IRL*) & Gerhard Krönke (*AUT*)16:15 - 16:50 **Metabolic regulation of tissue homeostasis by macrophages**
Thomas Weichhart (*Vienna, Austria*)16:50 - 17:15 **A tissue-level perspective on inflammation**
Stefan Uderhardt (*Erlangen, Germany*)17:15 - 17:25 **Synovial tissue macrophage loss of homeostasis predates clinical onset of rheumatoid arthritis (OP 01)**
Megan Hanlon (*Dublin, Ireland*)17:25 - 17:35 **Fate and contribution of tissue-resident and blood-derived macrophages to healthy and diseased synovial niches (OP 02)**
Gabriel Courties (*Montpellier, France*)17:35 - 17:45 **Single-cell chromatin and transcriptome dynamics of synovial fibroblasts transitioning from homeostasis to pathology in TNF-driven arthritis (OP 03)**
Maria Sakkou (*Athens, Greece*)**17:45 - 18:30 KEYNOTE LECTURE****Chair:** Günter Steiner (*AUT*)**Role of Pax5 in B cell development, immunity and disease**
Meinrad Busslinger (*Vienna, Austria*)**19:00 - 22:00 WELCOME RECEPTION and NETWORKING DINNER at the hotel**



Friday, May 6, 2022 (Day 2)

08:30 - 10:00 SESSION 2 - GENES AND BIOMARKERS

Chair: Natalie Lambert (FR) & René Toes (NL)

08:30 - 09:05 **Polygenic risk scores and rheumatology**

Matthew Brown (London, UK)

09:05 - 09:30 **Autoreactivity to protein modifications in rheumatoid arthritis**

Caroline Grönwall (Stockholm, Sweden)

09:30 - 09:40 **Polyclonal and monoclonal anti-citrullinated autoantibody response induced by COVID-19 disease but not by SARS-Cov-2 vaccination in rheumatoid arthritis patients (OP 04)**

Karl Skriner (Berlin, Germany)

09:40 - 09:50 **Comparison between miRNA biomarker expression and endothelial cell pathogenicity in rheumatoid arthritis and psoriatic arthritis (OP 05)**

Orla Tynan (Dublin, Ireland)

09:50 - 10:00 **Screening for circulating miRNAs characterizing patients with difficult-to-treat rheumatoid arthritis (OP 06)**

Jiri Baloun (Prague, Czech republic)

10:00 - 10:30 **Coffee break and poster viewing**



10:30 - 12:00 SESSION 3 - EPIGENETICS

Chair: Michael Bonelli (AUT) & Caroline Ospelt (CH)

10:30 - 11:05 **Epigenetics of inflammatory arthritis: Biological determinants and clinical applications**

Esteban Ballestar (Barcelona, Spain)

11:05 - 11:30 **Methylation matters: Unravelling the OA epigenome**

Sarah Rice (Newcastle upon Tyne, UK)

11:30 - 11:40 **miRNA profiling of peripheral blood mononuclear cells in patients with axial spondyloarthritis (OP 07)**

Aneta Pekacova (Prague, Czech Republic)

11:40 - 11:50 **Anatomical transcriptional diversity of Homeobox D transcription factors translates into joint-specific synovial fibroblast phenotypes (OP 08)**

Masoumehalsadat Mirrahimi (Zurich, Switzerland)

11:50 - 12:00 **T cell priming of a specific activation state in CD34 positive synovial tissue fibroblasts that drives T cell recruitment to the joint (OP 09)**

Samuel Kemble (Birmingham, UK)

12:00 - 12:30 **Lunch Break**



12:30 - 14:00 POSTER PRESENTATIONS and GUIDED POSTER TOURS**14:00 - 15:30 SESSION 4 - INNATE IMMUNE CELLS**

Chair: Attila Mocsai (HUN) & Andreas Radbruch (GER)

- 14:00 - 14:35 **Signatures of innate lymphoid cell activation and differentiation**
Chiara Romagnani (Berlin, Germany)
- 14:35 - 15:00 **The SLC15A4/TASL complex – A new element in the pathogenesis of SLE?**
Leonhard Heinz (Vienna, Austria)
- 15:00 - 15:10 **Eosinophils control arthritis-induced bone loss by inhibiting osteoclasts through eosinophil peroxidase** (OP 10)
Darja Andreev (Erlangen, Germany)
- 15:10 - 15:20 **Origin and role of macrophage subsets in the pathophysiology of osteoarthritis** (OP 11)
Damien Laouteouet (Montpellier, France)
- 15:20 - 15:30 **Maladaptive activation of trained immunity in the pathogenesis and treatment of giant cell arteritis** (OP 12)
Giulio Cavalli (Milan, Italy)

15:30 - 16:00 Coffee break and poster viewing**16:00 - 17:30 SESSION 5 - REGENERATIVE MEDICINE AND SENESCENCE**

Chair: Joanna Sherwood (GER) & Lisa van Baarsen (NL)

- 16:00 - 16:35 **Tissue regeneration and aging: the senescence connection**
Johannes Grillari (Vienna, Austria)
- 16:35 - 17:00 **Targeting senescent cells in osteoarthritis: an innovative therapeutic approach**
Danièle Noel (Montpellier, France)
- 17:00 - 17:10 **NOS inhibition reverses TLR2-induced chondrocyte dysfunction and attenuates age-related osteoarthritis** (OP 13)
Ping Shen (Berlin, Germany)
- 17:10 - 17:20 **Synovial fibroblasts in osteoarthritis are marked by pathologically overexpressed pyruvate dehydrogenase kinases** (OP 14)
Alexandra Damerou (Berlin, Germany)
- 17:20 - 17:30 **Role of NRG/ErbB signaling axis in cartilage regeneration in zebrafish** (OP 15)
Farida Djouad (Montpellier, France)

17:30 - 18:15 KEYNOTE LECTURE

Chair: Hans Kiener (AUT)

Cardioids reveal self-organising principles of human cardiogenesis
Sasha Mendjan (Vienna, Austria)



Saturday, May 7, 2022 (Day 3)

08:30 - 10:00

SESSION 6 - B CELLS AND T CELLS

Chair: Hyun-Dong Chang (GER) & Vivi Malmström (SWE)

08:30 - 09:05

Autoimmunity and neuroinflammation in fibromyalgia

Camilla Svensson (Stockholm, Sweden)

09:05 - 09:30

Synovial T cell polyfunctionality in inflammatory arthritis

Achilleas Floudas (Dublin, Ireland)

09:30 - 09:40

Peripheral mononuclear cells of RA patients initiate arthritis in NSG-DR4 mice (OP 16)

Janine Rupp (Graz, Austria)

09:40 - 09:50

IRF1-mediated ATR DNA damage response signaling drives B cell hyperreactivity in systemic lupus erythematosus (OP 17)

Theodora Manolakou (Athens, Greece)

09:50 - 10:00

IgM myeloperoxidase (MPO)-specific B cell expansion in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OP 18)

Hans Ulrich Scherer (Leiden, The Netherlands)

10:00 - 10:30

Coffee break and poster viewing



10:30 - 12:00

SESSION 7 - ORGAN AND TISSUE INFLAMMATION

Chair: Maurizio Cutolo (IT) & Zoltan Szekanecz (HUN)

10:30 - 11:00

Myositis from bedside to bench, and back again

Ingrid Lundberg (Stockholm, Sweden)

11:00 - 11:30

Recent advances in understanding pathogenesis and therapy of scleroderma

Oliver Distler (Zürich, Switzerland)

11:30 - 11:40

miR-221/222 regulate synovial fibroblast expansion and pathogenesis of TNF-mediated arthritis (OP 19)

Fani Roumelioti (Vari, Greece)

11:40 - 11:50

Inside the joint of inflammatory arthritis patients: handling and processing of synovial tissue biopsies for high throughput analysis (OP 20)

Viviana Marzaioli (Dublin, Ireland)

11:50 - 12:00

Reset of inflammatory priming of joint tissue and reduction of the severity of arthritis flares by bromodomain inhibition (OP 21)

Markus Hoffmann (Lübeck, Germany)

12:00 - 12:30

Lunch Break



12:30 - 14:00 **POSTER PRESENTATIONS and GUIDED POSTER TOURS**

12:30 - 14:00 **International Advisory Board Meeting (Room Create)**

14:00 - 15:30 **SESSION 8 - JOINT DEGENERATION AND REPAIR**

Chair: Silvia Hayer (AUT) & Marije Koenders (NL)

14:00 - 14:30 **An in silico perspective on osteoarthritis**

Liesbet Geris (*Leuven, Belgium*)

14:30 - 15:00 **Amelioration of bone loss by resolution of inflammatory pathways in arthritis**

Aline Bozec (*Erlangen, Germany*)

15:00 - 15:10 **The physiological hypoxic environment of articular cartilage triggers DOT1L expression to protect against osteoarthritis (OP 22)**

Astrid de Roover (*Leuven, Belgium*)

15:10 - 15:20 **Targeting cartilage damage as a trigger of mesenchymal activation in destructive joint diseases (OP 23)**

Sarah Bödecker (*Münster, Germany*)

15:20 - 15:30 **The availability of serine is critical for osteoclast differentiation (OP 24)**

Markus Kieler (*Vienna, Austria*)

15:30 - 16:00 **Coffee break and poster viewing**



16:00 - 17:30 **SESSION 9 - PRECISION MEDICINE AND NOVEL TARGETS**

Chair: Daniel Aletaha (AUT) & Andrew Cope (UK)

16:00 - 16:35 **The implications of the human cell atlas for targeting fibroblasts in immune mediated inflammatory diseases**

Christopher Buckley (*Oxford, UK*)

16:35 - 17:00 **The long and winding road from health to disease**

Diane van de Woude (*Leiden, The Netherlands*)

17:00 - 17:10 **Digital spatial profiling reveals distinct synovial tissue macrophage transcriptomic signature of sustained remission in rheumatoid arthritis patients at risk of disease flare after treatment cessation (OP 25)**

Stefano Alivernini (*Rome, Italy*)

17:10 - 17:20 **Metabolic imbalance of synovial fibroblasts in individuals at risk of rheumatoid arthritis (OP 26)**

Tineke de Jong (*Amsterdam, The Netherlands*)

17:20 - 17:30 **Proof-of-concept of fibroblast-targeted photodynamic therapy in human 3D scleroderma skin model and bleomycin-induced skin fibrosis in mice (OP 27)**

Daphne Dorst (*Nijmegen, The Netherlands*)

17:30 - 18:15

KEYNOTE LECTURE

Chair: Daniel Aletaha (AUT)

**Molecular portraits of rheumatoid arthritis:
Defining clinical and treatment response endotypes towards
precision medicine**

Costantino Pitzalis (London, UK)

18:15 - 18:30

AWARD CEREMONY – EULAR Abstract prizes

18:30 - 18:45

EWRR 2023 - A glimpse of Dublin

18:45 - 18:50

CLOSING REMARKS

20:00 - 24:00

NETWORKING EVENT and FAREWELL DINNER at Wolke 19



Friday, May 6

12:30 - 14:00 POSTER TOURS 1, 3, 5, 6, 8, 11

INNATE IMMUNITY

ROOM: CONGRESS HALL (ground floor)

Poster Tour Leaders: Pierre Miossec (FR) & Clemens Scheinecker (AUT)

- P 01.01 CTLA-4 INDUCED TOLEROGENIC DCS EXERT THEIR FUNCTION THROUGH ALTERATIONS IN CELLULAR METABOLISM
P. Goutakoli*, G. Papadaki, S. Papanikolaou, G. Vatsellas, G. Bertias, P. Verginis, P. Sidiropoulos
- P 01.02 DIFFERENTIAL STAT ACTIVATION IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
B. Dreo*, A. Muralikrishnan, R. Husic, J. Fessler, A. Lackner, P. Bosch, J. Rupp, A. Buchmann, M. Khalil, J. Thiel, M. Stradner
- P 01.03 NEUTROPHIL EXTRACELLULAR TRAPS TRIGGER AN ENHANCED PRO-INFLAMMATORY RESPONSE IN MACROPHAGE SUBPOPULATIONS IN RHEUMATOID ARTHRITIS PATIENTS
D. Melbouci, S. Seninet, M. Boissier, E. Segura, P. Decker*
- P 01.04 ELEVATED SERUM IL-40 IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS AND ITS ASSOCIATION WITH AUTOANTIBODIES, NEUTROPHIL ACTIVATION AND NETOSIS
A. Navrátilová*, V. Bečvář, H. Hulejová, K. Pavelka, J. Vencovský, L. Šenolt, L. Andrés Cerezo
- P 01.05 REGULATION OF BAFF EXPRESSION THROUGH THE INTERFERON- α AUTOPHAGY AXIS: IMPLICATIONS FOR SYSTEMIC LUPUS ERYTHEMATOSUS
D. Nikoleri*, K. Gkirtzimanaki, S. Georgakis, P. Verginis, P. Sidiropoulos, G. Bertias
- P 01.06 INCREASED NEUTROPHIL FREQUENCY IN LYMPH NODES OF PATIENTS WITH PSORIATIC ARTHRITIS
A. M. O'Byrne*, J.W. Bolt, C. M. J. van Ansenwoude, J. F. Semmelink, M. Maas, M. G. H. van de Sande, L. G. M. van Baarsen
- P 01.07 IL-23 SIGNALING INDUCES AUTOIMMUNE DISEASE GENES IN MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS
L. Rogge*, T. Stephen, V. Guillemot, C. Leloup, I. Mezghiche, H. Yahia-Cherbal, N. Pietrosevoli, E. Bianchi
- P 01.08 INTERACTIONS BETWEEN SYNOVIAL FIBROBLASTS AND INNATE IMMUNE CELLS IN EXPERIMENTAL ARTHRITIS
E. Kaposztas, L. Balogh, A. Maklari, A. Mocsai, T. Nemeth*
- P 01.09 THE ROLE OF SYK IN MONOSODIUM URATE CRYSTAL-INDUCED INFLAMMATION
K. Futosi*, K. Tomcsányi, S. Tusnády, A. Mócsai

- P 01.10 LOW-DOSE RADIOTHERAPY WITH X-RAYS AND RADON RESULTS IN DIVERSE IMMUNOLOGICAL ALTERATIONS IN A MOUSE MODEL OF RHEUMATOID ARTHRITIS
L. Deloch*, M. Rückert, A. Maier, A. Hinrichs, T. Weissmann, M. Seeling, F. Nimmerjahn, A. Flohr, D. Eckert, C. Fournier, R. Fietkau, B. Frey, U. S. Gaipl
- P 01.11 CTLA4-IG INDUCES M2 POLARIZATION OF CULTURED M1 MACROPHAGES OBTAINED FROM RHEUMATOID ARTHRITIS PATIENTS AND HEALTHY SUBJECTS
M. Cutolo, E. Gotelli, S. Tardito, P. Montagna, R. Campitiello, S. Paolino, C. Pizzorni, A. Sulli, V. Smith, S. Soldano*
- P 01.12 COMPETITIVE INHIBITION FOR TRANSCRIPTIONAL REGULATION OF GILZ BY TYPE I IFN AND GLUCOCORTICOIDS
W. Dankers*, M. Northcott, T. Bennett, A. D'Cruz, R. Sherlock, J. Gearing, P. Hertzog, B. Russ, I. Miceli, W. McHenry, S. Scheer, M. Fujishiro, K. Hayakawa, K. Ikeda, E. Morand, S. Jones
- P 01.13 CHARACTERIZATION OF CONDITIONALLY IMMORTALISED, CAS9 EXPRESSING MYELOID PROGENITORS
Á. Pánczél*, M. Havasi, A. Orosz, A. Mócsai

T CELLS

ROOM: CONGRESS HALL (*ground floor*)

Poster Tour Leaders: *Vivi Malmström (SWE) & Frédérique Ponchel (FR)*

- P 03.01 IDENTIFICATION OF AUTOREACTIVE T CELLS AND THEIR TCR REPERTOIRE IN ANCA ASSOCIATED VASCULITIS
R. Kumar*, N. Yoosuf, M. Afonso, A. Scheffschick, A. Avik, A. Bartoletti, B. Raposo, S. Boddul, A. Jonasdottir, B. Lövrström, K. Chemin, A. Bruchfeld, I. Gunnarsson, V. Malmström
- P 03.02 INCREASED FREQUENCY OF CD4+AND CD8+FOLLICULAR HELPER T CELLS IN HUMAN LYMPH NODE BIOPSIES DURING THE EARLIEST STAGES OF RHEUMATOID ARTHRITIS
D. Anang*, T. H. Ramwadhoebe, J. Hahnlein, B. van Kuijk, N. Smits, K. van Lienden, M. Maas, D. Gerlag, P. Tak, N. de Vries, L. van Baarsen
- P 03.03 CHARACTERISING THE FUNCTIONAL RESPONSE OF ANTIGEN SPECIFIC CD4+ T CELLS IN RHEUMATOID ARTHRITIS
K. Steel*, E. Pook, S. Ryan, M. Chin, E. Perucha, A. Cope, Y. Abraham
- P 03.04 INVOLVEMENT OF A NOVEL PD-1+ EFFECTOR MEMORY T CELL SUBPOPULATION IN THE PATHOPHYSIOLOGY OF RHEUMATOID ARTHRITIS
M. Lacaud*, M. Breckler, M. Boissier, N. Bessis, J. Biton
- P 03.05 ACETATE EXPOSURE REDUCES T CELL FILAMENTOUS ACTIN BRANCHING AND MIGRATION
V. Azizov*, M. Frech, M. Kubankova, Z. Winter, J. Hofmann, S. Kempa, D. Lapuente, M. Tenbusch, J. Guck, G. Schett, M. M. Zaiss

- P 03.06 CITRULLINATED-PEPTIDE INDUCED CD4+ T CELL RESPONSES IN RHEUMATOID ARTHRITIS
J. D. Swift*, A. E. Anderson, A. G. Pratt, J. D. Isaacs
- P 03.07 DEEP IMMUNE PHENOTYPING OF T LYMPHOCYTE SUBSETS IN SYSTEMIC SCLEROSIS PATHOPHYSIOLOGY AND FOLLOWING RESPONSE TO TARGETED CYTOTOXIC TREATMENT
T. I. Papadimitriou*, A. P. M. van Caam, J. M. J. Lemmers, X. He, E. L. Vitters, M. I. Koenders, R. L. Smeets, M. C. Vonk, P. M. van der Kraan, H. J. P. M. Koenen, R. M. Thurlings
- P 03.08 MODIFICATION OF REGULATORY T CELLS IDENTITY DURING CHRONIC INFLAMMATION IN PATIENTS WITH RHEUMATOID ARTHRITIS OR SPONDYLOARTHRITIS
L. Mebrek, T. Abaab, M. Boissier, L. Semerano, J. Biton, N. Bessis
- P 03.09 DIFFERENTIAL EFFECTS OF IL-23 AND IL-17 FAMILY MEMBERS ON CELL INTERACTIONS BETWEEN IMMUNE CELLS AND STROMAL CELLS
I. Tout*, M. Noack, P. Miossec
- P 03.10 THE METABOLIC, RATHER THAN INFLAMMATORY, PROFILE DISTINGUISHES RHEUMATOID ARTHRITIS CD8 T-CELLS FROM HEALTHY DONORS
F. V. Kraus*, T. Fleming, D. Helm, M. Schneider, C. D. Langhans, F. Kratzer, R. A. Carvalho, J. G. Okun, H. M. Lorenz, M. M. Souto-Carneiro

CARTILAGE & BONE

ROOM: CONGRESS HALL (ground floor)

Poster Tour Leaders: Adelheid Korb-Pap (GER) & Stefan Tögel (AUT)

- P 05.01 INHIBITION OF HISTONE DEMETHYLASES AS AN APPROACH TO RESTORE DEFICIENT DOT1L ACTIVITY IN CARTILAGE TO TREAT OSTEOARTHRITIS
R. Assi*, C. Cherifi, F. Cornelis, R. Lories, S. Monteagudo
- P 05.02 HYPOXIA AND INHIBITION OF WNT SIGNALING PROMOTE EXPRESSION OF THE PROTECTIVE MOLECULE ANP32A IN CARTILAGE
J. Quintiens*, F. M. F. Cornelis, A. De Roover, A. Escribano Núñez, S. Monteagudo, R. Lories
- P 05.03 TYPE H BLOOD VESSELS LINK PATHOLOGICAL OSTEOGENESIS AND INFLAMMATION IN EXPERIMENTAL SPONDYLOARTHRITIS
M. H. Kaaij, J. P. van Hamburg*, C. C. N. van Rooijen, Y. Y. Kan, D. Pots, L. F. A. Huitema, L. J. van Ruijven, A. Grüneboom, G. Schett, L. M. van Duivenvoorde, D. L. P. Baeten, S. W. Tas
- P 05.04 HEM1-DEFICIENCY PROTECTS AGAINST HTNF-MEDIATED TRABECULAR BONE LOSS IN FEMORA
E. Werbenko*, J. Reinhardt, F. Geers, C. Wehmeyer, M. Dienstbier, P. Paruzel, T. E. B. Stradal, D. J. J. de Gorter, T. Pap, B. Dankbar



- P 05.05 INTEGRIN A11B1 AFFECTS THE PROGRESSION OF DISEASE AND JOINT DESTRUCTION IN THE ARTHRITIC HTNFTG MOUSE
A. De Giuseppe*, A. Deichsel, K. Rauwolf, I. Zeinert, N. Lu, D. Beckmann, U. Hansen, D. Kronenberg, D. Gullberg, B. Eckes, T. Pap, A. Korb-Pap
- P 05.06 DENDRITIC CELLS ARE IMPORTANT OC PRECURSORS IN VIVO
A. Mazzucato-Puchner*, E. Simader, V. Saferding, B. Niederreiter, M. Hoffman, J. Brunner, R. Pfeiffle, G. Krönke, G. Schabbauer, M. Kieler, M. Kuttke, G. Steiner, D. Aletaha, J. Smolen, S. Blüml
- P 05.07 TNF α MEDIATED CARTILAGE DAMAGE IS REDUCED BY FLUIDIC SHEAR STRESS: A 3D MODEL OF DEGENERATIVE JOINT DISEASE
A. Damerau*, D. Do Nguyen, C. Lubahn, T. Leeuw, F. Buttgereit, T. Gaber
- P 05.08 ESTABLISHMENT OF 3D CO-CULTURES USING SYNOVIAL FIBROBLASTS AND CARTILAGE
J. de Souza Silva*, F. Bischoff, A. De Giuseppe, L. Seseña Carillo, U. Hansen, H. Kiener, T. Pap, A. Korb-Pap
- P 05.09 MECHANICAL REGULATION AND THE INTERPLAY BETWEEN PIEZO1 AND TRPV4 IN HUMAN PRIMARY OA CHONDROCYTES
B. Steinecker-Frohnwieser*, C. Kratschmann, M. Cezanne, S. Toegel, L. Weigel
- P 05.10 THE GLYCOBIOLOGICAL ROLE OF GALECTINS IN THE PATHOGENESIS OF DEGENERATIVE JOINT DISEASES
S. Toegel*, S. Hayer, K. Pichler, S. Schmidt, R. Windhager
- P 05.11 TRANSCRIPTION FACTOR REPORTERS SUITABLE FOR MONITORING PATIENT DEPENDENT CHONDROGENIC CAPACITY IN OSTEOARTHRITIS
P. M. van der Kraan*, M. M. Neefjes, B. A. C. Housmans, T. J. M. Welting, A. P. M. Caam
- P 05.12 MODULATION OF DIFFERENTIATION AND BONE-RESORBING ACTIVITY OF OSTEOCLASTS AFTER X-RAY EXPOSURE
D. Eckert*, F. Rapp, A. Tsedeke, D. Kraft, I. Wente, J. Molendowska, S. Basheer, T. Friedrich, C. Fournier

ORGAN AND TISSUE INFLAMMATION 1

ROOM: TRANS SIBERIAN / TEXAS EAGLE / ORIENT EXPRESS (*TSTEOE*) (1st floor)

Poster Tour Leaders: Gyorgy Nagy (HUN) & Ladislav Senolt (CZ)

- P 06.01 DISTINCT STROMAL AND IMMUNE CELL INTERACTIONS SHAPE THE PATHOGENESIS OF RHEUMATOID AND PSORIATIC ARTHRITIS
A. Floudas*, C. Smith, O. Tynan, N. Nuno, V. Krishna, S. Wade, M. Hanlon, C. Cunningham, V. Marzaioli, M. Canavan, J. Fletcher, R. Mullan, S. Cole, L. Hao, S. Nagpal, M. Monaghan, D. Veale, U. Fearon
- P 06.02 PROPIONATE INDUCED BACTERIAL-DERIVED HISTAMINE PROMOTES RESOLUTION OF SYNOVIAL INFLAMMATION
K. Dürholz*, S. Lucas, E. Schmid, F. Schälter, M. Frech, V. Azizov, J. Hofmann, A. Iljazovic, T. Strowig, R. Taudte, M. Fromm, W. Xiang, C. Akdis, G. Schett, M. Zaiss

- P 06.03 COMBINED SINGLE CELL PROFILING TECHNOLOGIES REVEAL NOVEL MODULATION OF WNT SIGNALLING IN SYNOVIAL FIBROBLASTS DURING THE RESOLUTION PHASE OF INFLAMMATORY ARTHRITIS
L. Marsh*, S. Kemble, C. B. Mahoney, J. D. Turner, P. R. Nisa, A. P. Croft
- P 06.04 SYNOVIAL TISSUE ZONATION UNDERPINS SPECIFIC DISEASE PATHOTYPES IN RHEUMATOID ARTHRITIS
P. R. Nisa*, C. G. Smith, C. B. Mahoney, S. Kemble, L. Marsh, A. Hackland, A. P. Croft
- P 06.05 HISTOLOGICAL CHANGES IN THE SYNOVIUM TO DEFINE REMISSION IN RHEUMATOID ARTHRITIS
S. Ohl*, K. Frommer, M. Rickert, S. Rehart, U. Müller-Ladner, E. Neumann
- P 06.06 A CRITICAL ROLE FOR TNFR2 IN RHEUMATOID ARTHRITIS FIBROBLAST-LIKE SYNOVIOCYTE (RA-FLS) ACTIVATION
T. Suto, A. Tosevska, K. von Dalwigk, M. Kugler, M. Dellinger, I. Stanic, A. Platzer, B. Niederreiter, F. Sevelde, M. Bonelli, T. Pap, H. Kiener, K. Okamura, H. Chikuda, D. Aletaha, L. Heinz, T. Karonitsch*
- P 06.07 INVESTIGATING THE IMPACT OF TWO-PORE CHANNEL 1 DEFICIENCY ON ANTIGEN-INDUCED ARTHRITIS
B. Sehnert*, K. K. Witezek, R. T. Mallmann, R. Rzepka, N. Chevalier, N. Klugbauer, R. E. Voll
- P 06.08 PET/CT ASSESSMENT OF JOINT AND VASCULAR INFLAMMATION IN TOFACITINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS
A. Hamar*, Z. Hascsi, A. Pusztai, M. Czókolyová, E. Végh, Z. Pethő, K. Gulyás, B. Soós, G. Kerekes, É. Szekanez, K. Hodosi, S. Szántó, G. Szűcs, T. Seres, Z. Szekanez, S. Szamosi
- P 06.09 INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC AUTOIMMUNE DISEASE. TREATMENT AND SURVIVAL
C. Trapero Pérez*, N. Roldan Ruiz, S. Rodriguez Montero, J. Marenco de la Fuente
- P 06.10 SERUM GRANULOCYTE-MONOCYTE COLONY STIMULATING FACTOR (GM-CSF) IS INCREASED IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS) AND PERSISTS DESPITE ANTI-TNF TREATMENT
C. Papagoras, S. Tsiami, A. Chrysanthopoulou, I. Mitroulis, C. Schütz*, X. Baraliakos

FROM AT-RISK TO DISEASE**ROOM:** TRANS SIBERIAN / TEXAS EAGLE / ORIENT EXPRESS (*TSTEOE*) (1st floor)**Poster Tour Leaders:** Arthur Pratt (UK) & Paul Studenic (AUT)

- P 08.01 LYMPHOCYTE SUBSETS PHENOTYPING FOR THE PREDICTION OF PROGRESSION TO INFLAMMATORY ARTHRITIS IN ACPA+AT-RISK INDIVIDUALS
I. Anioke, L. Duquenne, F. Shuweihi, K. Mankia, P. Emery, F. Ponchel*
- P 08.02 DYSREGULATION OF $\gamma\delta$ -T CELLS IN INDIVIDUALS AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS
K. Prajzlerová*, O. Kryštůfková, P. Hánová, H. Hulejová, N. Petrovská, J. Vencovský, L. Šenolt, M. Filková

- P 08.03 AUTOREACTIVE MEMORY B CELLS IN RHEUMATOID ARTHRITIS: KEY TO UNDERSTANDING IMMUNOLOGICAL DISEASE ACTIVITY
N. J. Blomberg, H. Kristyanto, M. Verstappen, S. Neppelenbroek, A. S. B. Kampstra, A. H. M. van der Helm-van Mil, R. E. M. Toes, H. U. Scherer*
- P 08.04 A HISTORY OF CHLAMYDIAE INFECTION IN RHEUMATOID ARTHRITIS DEVELOPMENT
C. Lamacchia*, R. Aymon, B. Gilbert, O. Studer, K. Lauper, A. Finckh
- P 08.05 TARGETING DRAINING LYMPH NODE STROMAL CELLS TO PREVENT DISEASE ONSET IN COLLAGEN-INDUCED ARTHRITIS
F. Schälter*, V. Azizov, M. Frech, K. Dürholz, M. Sokolova, A. Hendel, K. Focke, K. Sarter, L. G. M. van Baarsen, S. Krautwald, G. Schett, M. M. Zaiss
- P 08.06 T CELL RESPONSES IN A PRECLINICAL MOUSE MODEL OF COLLAGEN-INDUCED ARTHRITIS
H. Garibagaoglu*, R. Pfeifle, K. Ziegler-Martin, G. Schett, G. Krönke
- P 08.07 FACTORS ASSOCIATED WITH ADVERSE PREGNANCY OUTCOMES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
C. Sieiro Santos*, C. Moriano Morales, C. Álvarez Castro, E. Díez Álvarez
- P 08.08 FACTORS ASSOCIATED WITH ADVERSE OUTCOMES IN UVEITIS RELATED TO SPONDYLARTHROSIS (SPA-U)-DEVELOPMENT OF A PROGNOSTIC OUTCOME SCORE IN PATIENTS WITH SPA-U
C. Sieiro Santos*, I. Sendino Tenorio, C. Álvarez Castro, M. Cordera Coma, C. Moriano Morales, E. Díez Álvarez
- P 08.09 T CELL-DERIVED GM-CSF AS A REGULATIVE ELEMENT DURING THE ONSET OF AUTOANTIBODY-MEDIATED ARTHRITIS
R. Pfeifle*, V. Hoernig, G. Kroenke
- P 08.10 ANTI-ACETYLATED PROTEIN IGM-ANTIBODIES AS POSSIBLE STARTING POINT OF AUTOANTIBODY FORMATION IN RHEUMATOID ARTHRITIS
S. Reijm*, T. J. van Wesemael, A. Kawakami, T. Maeda, S. Kawashiri, T. W. J. Huizinga, M. Tamai, R. E. M. Toes, D. van der Woude

GENETICS AND EPIGENETICS

ROOM: BLUE TRAIN (1st floor)

Poster Tour Leaders: Niek de Vries (NL) & Sarah Rice (UK)

- P 11.01 TRANSCRIPTION FACTOR PRIMING CONTROLS SYNOVIAL FIBROBLAST SUBSET ACTIVATION IN INFLAMMATORY ARTHRITIS
C. B. Mahony*, S. Kemble, L. Marsh, J. Turner, A. P. Croft
- P 11.02 DNA HYPO-METHYLATION OF THE TNF GENE PROMOTER PREDICTS RHEUMATOID ARTHRITIS CLASSIFICATION IN PATIENTS WITH EARLY INFLAMMATORY SYMPTOMS
R. Pitaksalee, F. Shuweihi, R. Parmar, P. Emery, F. Ponchel*

- P 11.03 FUNCTIONAL CHARACTERIZATION OF RARE VARIANTS IN THE OAT1 AND OAT3 URATE TRANSPORTERS IDENTIFIED IN HYPERURICEMIA/GOUT COHORT
K. Pavelcova*, J. Vavra, A. Mancikova, L. Hasikova, B. Stiburkova
- P 11.04 HLA-DRB1*13 ASSOCIATES POSITIVELY AND HLA-DRB1*03 NEGATIVELY WITH ANTI-PHOSPHATIDYL SERINE/PROTHROMBIN ANTIBODIES AND VASCULAR EVENTS IN SLE
S. Elbagir, L. M. Diaz-Gallo, G. Grosso, A. Zickert, I. Gunnarsson, M. Mahler, E. Svenungsson, J. Rönnelid*
- P 11.05 EXPLORING MICRO-RNA CONTENT OF CIRCULATING EXTRACELLULAR VESICLES AS BIOMARKERS IN EARLY RHEUMATOID ARTHRITIS
D. Maunder, P. M. Brown, B. Barron-Millar, A. E. Anderson, N. Naamane, J. MacDonald, D. W. Lendrem, N. Wang, W. Morgan, S. L. Mackie, R. E. Crossland, A. G. Pratt1
- P 11.06 NO CAUSAL LINK BETWEEN ADIPONECTIN AND RISK OF DEVELOPING RHEUMATOID ARTHRITIS IN BOTH EUROPEANS AND EAST ASIANS: A TWO-SAMPLE MULTIVARIABLE MENDELIAN RANDOMIZATION STUDY
G. Vasileiadis*, T. Fatima, C. Maglio
- P 11.07 ANTI-INFLAMMATORY EFFECTS OF THE CBP-P300 INHIBITOR A-485 ON THE MURINE CHONDROGENIC CELL LINE ATDC5 AND HUMAN DERMAL FIBROBLASTS
B. Kloesch*, M. Trummer, M. Reiff, B. Mayer, A. Schrammel, G. Steiner
- P 11.08 CROSSTALK OF SYNOVIAL MACROPHAGES AND FIBROBLAST DURING THE COURSE OF RHEUMATOID ARTHRITIS
D. Chambers*, K. Knab

Saturday, May 7

12:30 - 14:00 POSTER TOURS 2, 4, 7, 9, 10, 12

B CELLS

ROOM: CONGRESS HALL (ground floor)

Poster Tour Leaders: Dagmar Scheel-Töllner (UK) & Hans-Ulrich Scherer (NL)

- P 02.01 PROTEOGENOMIC ANALYSIS OF THE AUTOACTIVE B CELL REPERTOIRE IN BLOOD AND TISSUES OF PATIENTS WITH SJÖGREN'S SYNDROME
R. Thurlings*
- P 02.02 MONOCLONAL ANTIBODIES FROM B CELLS OF PATIENTS WITH ANTI-MDA5 ANTIBODY-POSITIVE DERMATOMYOSITIS DIRECTLY STIMULATE INTERFERON GAMMA PRODUCTION
F. Coutant*, R. Bachet, J. Pin, M. Alonzo, P. Miossec
- P 02.03 MULTIREACTIVE ANTI-CITRULLINATED PROTEIN AUTOANTIBODIES DERIVED FROM RHEUMATOID ARTHRITIS PATIENT BONE MARROW PLASMA CELLS TARGET NEUTROPHILS
P. Sahlström*, K. Amara, A. Hensvold, R. Thyagarajan, R. Stålesen, M. Hansson, L. Israelsson, L. Klareskog, B. Rethi, A. I. Catrina, V. Malmström, C. Grönwall
- P 02.04 PHENOTYPING OF CROSS-REACTIVE AUTOANTIGEN-SPECIFIC B CELLS IN RHEUMATOID ARTHRITIS USING SPECTRAL FLOW CYTOMETRY
S. Reijm*, J. C. Kwekkeboom, N. J. Blomberg, J. Suurmond, H. U. Scherer, R. E. M. Toes
- P 02.05 IGA+ B CELLS WITH SPECIFICITY FOR GUT BACTERIA CAN BE IDENTIFIED IN THE JOINTS OF RA PATIENTS
J. A. Cameron*, R. Maier, K. Amara, R. Riedel, V. von Goetze, C. Gronwall, A. Filer, K. Raza, V. Malmstrom, H. Chang*, D. Scheel-Toellner
- P 02.06 B-CELL PHENOTYPE AND CAPACITY FOR DIFFERENTIATION ARE ALTERED IN OSTEOARTHRITIS
X. Xie, G. M. Doody, P. G. Conaghan, F. Ponchel*
- P 02.07 CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS HAVE ALTERATIONS IN B AND T FOLLICULAR CELL SUBSETS IN PERIPHERAL BLOOD
C. Tomé*, F. Oliveira-Ramos, R. Campanilho-Marques, A. F. Mourão, S. Sousa, A. T. Melo, R. L. Teixeira, A. P. Martins, P. Costa-Reis, R. P. Torres, M. Gonçalves, M. J. Santos, L. Graca, J. E. Fonseca, R. A. Moura
- P 02.08 CHILDREN WITH EXTENDED OLIGOARTICULAR AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS HAVE A CYTOKINE PROFILE IN PERIPHERAL BLOOD SUSTAINING B CELL ACTIVATION
C. Tomé*, F. Oliveira-Ramos, R. Campanilho-Marques, A. F. Mourão, S. Sousa, A. T. Melo, R. L. Teixeira, A. P. Martins, S. Moeda, P. Costa-Reis, R. P. Torres, H. Fonseca, M. Gonçalves, M. J. Santos, L. Graca, J. E. Fonseca, R. A. Moura

- P 02.09 STUDY OF SLAMF7/CS1 EXPRESSION IN PRIMARY GOUGEROT-SJÖGREN SYNDROME
C. Schleiss*, R. Felten, F. Monneaux, H. Dumortier, J. Gottenberg
- P 02.10 PHENOTYPICAL CHARACTERIZATION OF AUTOREACTIVE B CELLS IN RHEUMATOID ARTHRITIS
A. Wilhelm*, R. Pfeifle, G. Schett, G. Krönke

MESENCHYME**ROOM:** CONGRESS HALL (ground floor)**Poster Tour Leaders:** Markus Hoffmann (GER) & Thomas Karonitsch (AUT)

- P 04.01 RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS AND COLLAGEN IV ALPHA 2 ALTER NEOVASCULARIZATION IN VITRO
C. Heck*, D. Kürsammer, K. Frommer, M. Arnold, S. Rehart, U. Müller-Ladner, E. Neumann
- P 04.02 PROFILING OF OXYLIPINS IN SYNOVIAL INFLAMMATION AND RESOLUTION IN THE COLLAGENASE-INDUCED MOUSE MODEL OF OSTEOARTHRITIS
Q. Zhou*, F. Cornelis, M. Ghorasaini, M. Giera, S. Monteagudo, R. Lories
- P 04.03 ARP2/3 COMPLEX AND LASP1 ARE INVOLVED IN THE CELL-TO-CELL CONTACT FORMATION IN ARTHRITIC FIBROBLAST-LIKE SYNOVIOCYTES
D. Beckmann*, A. Krause, U. Hansen, H. Kiener, J. Kremerskothen, H. Pavenstädt, T. Pap, A. Korb-Pap
- P 04.04 FIBROBLAST-MACROPHAGE CROSSTALK VIA LACTATE: NEW THERAPEUTIC TARGET IN RHEUMATOID ARTHRITIS
V. Pucino*, M. Nefla, V. Gauthier, S. A. Clayton, A. Filer, A. R. Clark, K. Raza, C. D. Buckley
- P 04.05 THE INFLUENCE OF THE INFLAMMATORY CHONDRO-SYNOVIAL CROSS TALK ENVIRONMENT ON PATIENT-DERIVED HETEROTYPIC JOINT-ON-A-CHIP ORGANOID MODELS
M. Rothbauer*, E. I. Reihls, S. Toegel, R. Windhager, H. P. Kiener, P. Ertl
- P 04.06 ESTABLISHMENT OF A HUMAN SYNOVIUM-ON-A-CHIP FOR OSTEOARTHRITIS DISEASE-MODELING USING ANIMAL-FREE TECHNOLOGIES
E. I. Reihls*, S. Toegel, R. Windhager, P. Ertl, M. Rothbauer
- P 04.07 B-CELL INFLAMMATORY SIGNALS ATTENUATE CHONDROGENESIS OF HUMAN MESENCHYMAL STEM CELLS VIA DEVELOPMENTAL SIGNALING PATHWAYS
Y. Cai*, T. Hammersen, E. Tripel, H. Yao, J. Li, X. Guan, H. Lorenz, B. Moradi, T. Tretter
- P 04.08 INTERACTIONS BETWEEN IMMUNE CELLS AND SYNOVIOCYTES OR SKIN FIBROBLASTS HAVE OPPOSITE EFFECTS ON IL-23 PRODUCTION
M. Noack, I. Tout*, P. Miossec

- P 04.09 MOLECULAR INTERPLAY BETWEEN MAMMALIAN TARGET OF RAPAMYCIN MTOR AND THE HIPPO-YAP PATHWAY MEDIATES RA SYNOVIAL FIBROBLAST ACTIVATION
B. Barker*, M. Hanlon, S. Wade, D. J. Veale, U. Fearon, M. Canavan
- P 04.10 LOW-DOSE RADIOTHERAPY INDUCES GENDER- AND INFLAMMATORY BACKGROUND-SPECIFIC RESPONSES IN FIBROBLAST LIKE SYNOVIOCYTES
A. Völlings, M. Piltz, E. Titova, T. Wolff, T. Weissmann, R. Fietkau, B. Frey, U. S. Gaipf, L. Deloch*
- P 04.11 LOWER FREQUENCY OF HLA-DR+ LYMPH NODE STROMAL CELLS IN LYMPH NODE BIOPSIES OF PATIENTS WITH RHEUMATOID ARTHRITIS
C. Grasso*
- P 04.12 CYTOKINE SYNERGY ENHANCES SYNOVIAL FIBROBLAST ACTIVATION IN CHILDREN WITH DOWN'S SYNDROME-ASSOCIATED ARTHRITIS
S. Foo*, M. Canavan, V. Marzaioli, D. Veale, S. Wade, E. MacDermott, D. Deely, C. Foley, O. Killeen, U. Fearon

ORGAN AND TISSUE INFLAMMATION 2

ROOM: TRANS SIBERIAN / TEXAS EAGLE / ORIENT EXPRESS (*TSTOE*) (1st floor)

Poster Tour Leaders: Johannes Fessler (AUT) & Hans Kiener (AUT)

- P 07.01 MICROVASCULOPATHY IN SYSTEMIC SCLEROSIS: THE ROLE OF LONG NONCODING RNA H19X
F. Tirelli, E. Pachera*, R. Lafyatis, M. Huang, S. Assassi, E. Camarillo Retamosa, F. Zulian, G. Kania, O. Distler
- P 07.02 FOSL-2 AS A DRIVER OF MACROPHAGE PHAGOCYTOSIS IN SYSTEMIC SCLEROSIS
A. Hukara*, T. Tabib, M. Rudnik, O. Distler, P. Blyszczuk, R. Lafyatis, G. Kania
- P 07.03 MECHANICAL GATING OF TENDON FIBROGENIC TRANSCRIPTION IN SYSTEMIC SCLEROSIS
A. A. Hussien*, R. Knell, F. Renoux, S. L. Wunderli, B. Niederoest, M. R. Aronoff, J. Foolen, H. Wennemers, O. Distler, J. G. Snedeker
- P 07.04 THE MACROPHAGE MANNANOSE RECEPTOR AS NOVEL TARGET FOR PET IMAGING OF MACROPHAGES IN RHEUMATOID ARTHRITIS
M. M. Steinz*, J. Stuijt, F. Khodadust, N. Devoogdt, J. van Ginderachter, S. W. Tas, G. Jansen, J. van Hamburg, M. Schreurs, E. J. M. Kooijman, W. Beaino, A. D. Windhorst, C. van der Laken
- P 07.05 SOLUBLE GUANYLATE CYCLASE STIMULATION DAMPENS THE ANTIANGIOGENIC AND PROFIBROTIC PHENOTYPE OF SCLERODERMA ENDOTHELIAL CELLS: AN IN VITRO STUDY
B. S. Fioretto*, E. Romano, I. Rosa, D. Giuggioli, M. Matucci-Cerinic, M. Manetti
- P 07.06 PYROPHOSPHATE HAS LOW PLASMA LEVELS AND ABSORBS AFTER ORAL ADMINISTRATION IN SYSTEMIC SCLEROSIS PATIENTS
L. Kovács*, E. Kozák, M. Bocskai, G. Szűcs, S. Szamosi, L. Bálint, G. Kumánovics, L. Cziráj, A. Váradi

- P 07.07 EXPRESSION OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II IN IDIOPATHIC INFLAMMATORY MYOPATHIES
M. Robert, L. Lessard, T. Fenouil, B. Chazaud, M. Carlesimo, A. Bouche, A. Hot, T. Laumonier, N. Streichenberger, L. Gallay*
- P 07.08 TYPE-I INTERFERON SIGNALING IMPAIRS MUSCLE STEM CELL EXPANSION IN DERMATOMYOSITIS
L. Gallay*, L. Lessard, C. Fermon, M. Weiss-Gayet, S. Viel, N. Streichenberger, A. Corpet, R. Mounier, C. Gitiaux, G. Mouchiroud, B. Chazaud
- P 07.09 CLINICAL, SEROLOGICAL AND THERAPEUTIC EVALUATION OF MYOSITIS - RHEUMATOID ARTHRITIS OVERLAP PATIENTS IN A SINGLE HUNGARIAN CENTRE
L. Bodoki*, Z. Griger, M. Nagy-Vincze, Z. Betteridge, K. Dankó
- P 07.10 SRC-FAMILY KINASES IN IMMUNE COMPLEX-MEDIATED GLOMERULONEPHRITIS
L. S. Lesinszki*, L. K. Boldizsár, R. Michael, A. Mócsai
- P 07.11 THE EFFECT OF NEUTROPHIL-SPECIFIC DELETION OF PLCG2 IN EXPERIMENTAL AUTOIMMUNE SKIN BLISTERING
P. Koncz*, K. P. Szilveszter, A. Mócsai
- P 07.12 THE EFFECT OF PHOSPHOLIPASE C INHIBITION IN A HUMAN EX VIVO MODEL OF BULLOUS PEMPHIGOID
S. Vikár*, K. Szilveszter, M. Sárdy, A. Mócsai

PRECISION MEDICINE

ROOM: TRANS SIBERIAN / TEXAS EAGLE / ORIENT EXPRESS (*TSTEOE*) (1st floor)

Poster Tour Leaders: Amy Anderson (UK) & Stephan Blüml (AUT)

- P 09.01 MODULATION OF FOLLICULAR B AND T CELL SUBSETS BY LOW-DOSE IL-2 THERAPY IN PATIENTS WITH ACTIVE SLE
J. Y. Humrich*, C. von Spee-Mayer, E. Siegert, A. Rose, P. Enhgard, G. Riemekasten
- P 09.02 DECREASED SERUM SIRT1 AND SIRT3 IN SCLERODERMA: CORRELATION WITH SEVERITY OF SKIN AND PULMONARY FIBROSIS AND PERIPHERAL MICROVASCULAR DAMAGE
E. Romano, B. S. Fioretto*, I. Rosa, M. Matucci-Cerinic, M. Manetti
- P 09.03 IDENTIFYING NOVEL ORALLY ADMINISTERED SMALL MOLECULE INHIBITORS OF SYNOVIAL FIBROBLASTS' ARTHRITOGENIC ACTIVATION BASED ON REPURPOSING OF A KNOWN ANTIPSYCHOTIC DRUG
D. Papadopoulou*, V. Mavrikaki, F. Charalampous, F. Roumelioti, C. Tzaferis, N. Karagianni, M. Denis, A. Matralis, G. Kollias

- P 09.04 SEMIQUANTITATIVE ASSESSMENT OF SYNOVITIS ON US-GUIDED SYNOVIAL MEMBRANE BIOPSIES IS CONTINGENT ON DISEASE PHASE AND PREDICTIVE OF TREATMENT RESPONSE IN NAIVE TO TREATMENT PSORIATIC ARTHRITIS
D. Bruno*, B. Toluoso, M. Gessi, C. Di Mario, M. Gigante, L. Petricca, S. Perniola, A. Paglionico, V. Varriano, G. Peluso, L. Bul, A. Elmesmari, D. Somma, M. D'Agostino, M. Kurowska-Stolarska, E. Gremese, S. Alivernini
- P 09.05 ELECTRICAL STIMULATION OF THE SPLENIC NEUROVASCULAR BUNDLE HAS LONG-TERM THERAPEUTIC EFFICACY IN MURINE COLLAGEN-INDUCED ARTHRITIS, WHICH IS POTENTIATED WHEN APPLIED IN COMBINATION WITH A BIOLOGIC
T. Simon*, C. Panzolini, J. Lavergne, N. Hypolite, M. J. Vervoordeldonk, P. Blancou
- P 09.06 FOLYLPOLYGLUTAMATE SYNTHETASE MRNA SPLICING IN POLARIZED MACROPHAGES AND ACTIVATED T-CELLS: IMPACT FOR METHOTREXATE POLYGLUTAMYLATION
I. B. Muller, M. Lin, R. de Jonge, N. Will, R. G. Campos, E. A. Struys, C. van der Laken, Y. G. Assaraf, J. Cloos, A. Puig-Kroger, G. Jansen*
- P 09.07 METABOLIC REPROGRAMMING OF IL-1B STIMULATED RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS REDUCES THEIR INFLAMMATORY AND INVASIVE CAPABILITY
B. E. Barker*, M. M. Hanlon, S. Wade, D. J. Veale, M. Canavan, U. Fearon
- P 09.08 LOW DOSE RADIATION THERAPY APPLIED FOR CHRONIC DEGENERATIVE AND INFLAMMATORY DISEASES INDUCES LONG-LASTING PAIN REDUCTION AND DISTINCT IMMUNE MODULATIONS - RESULTS OF THE IMMO-LDRT01 TRIAL
A. Donaubaauer*, T. Weissmann, B. Fröhlich, I. Becker, O. J. Ott, R. Fietkau, U. S. Gaipl, B. Frey
- P 09.09 EFFECT OF METHOTREXATE AND FOLIC ACID CO-ADMINISTRATION IN ARTHRITIS
E. Dalix*, M. Maalouf, S. Peyroche, A. Vanden-Bossche, C. Arthaud, S. Hodin, R. Müller, H. Marotte
- P 09.10 SYNOVIAL FIBROBLASTS - T CELL INTERACTIONS ARE MAJOR DRIVERS OF INFLAMMATION: A CLOSER LOOK INTO THE JOINT
M. Kugler*, M. Dellinger, F. Kartnig, A. Tosevska, L. Müller, T. Preglej, L. Heinz, H. Kiener, G. Steiner, D. Aletaha, T. Karonitsch, M. Bonelli
- P 09.11 UPADACITINIB IN RHEUMATOID ARTHRITIS. REAL CLINICAL PRACTICE
N. Roldán Ruiz*, C. Ramos Giráldez, C. Azabal Pérez, R. Martínez Pérez, M. Velloso Feijóo, J. Marengo de la Fuente
- P 09.12 ANTIOXIDATIVE CAPACITY OF PATIENTS WITH DIABETES MELLITUS TYPE 2 AND DISEASES OF THE MUSCULOSKELETAL SYSTEM IN THE EVALUATION OF REHABILITATION
A. Odrovicsné-Tóth*, B. Thauerer, W. Kullich, B. Kirchberger, A. Kroell-Kalbhenn, S. Reimair, A. Salzer, B. Steinecker-Frohnwieser

AUTOANTIBODIES AND OTHER BIOMARKERS**ROOM:** BLUE TRAIN (1st floor)**Poster Tour Leaders:** *Caroline Grönwall (SWE) & Johan Ronnelid (SWE)*

- P 10.01 PROTEOMIC PROFILING TO IDENTIFY MARKERS OF METHOTREXATE RESISTANCE IN RHEUMATOID ARTHRITIS
J. Escal*, S. Hodin, E. Ollier, M. Poudret, H. Marotte, X. Delavenne
- P 10.02 IN RHEUMATOID ARTHRITIS PATIENTS, TOTAL IGA1 AND IGA2 LEVELS ARE ELEVATED; INDICATIONS OF A MUCOSAL ORIGIN
V. F. A. M. Derksen*, C. F. Allaart, A. H. M. van der Helm-van Mil, T. W. J. Huizinga, R. E. M. Toes, D. van der Woude
- P 10.03 AMPA CANNOT BE DETECTED IN FAECES OF SEROPOSITIVE RA PATIENTS: NO EVIDENCE FOR LOCAL AMPA PRODUCTION IN THE LOWER GASTRO-INTESTINAL TRACT
V. F. A. M. Derksen*, T. W. J. Huizinga, R. E. M. Toes, D. van der Woude
- P 10.04 IN RHEUMATOID ARTHRITIS, THE ASSOCIATION BETWEEN ANTI-MODIFIED PROTEIN ANTIBODIES AND LONG-TERM OUTCOMES IS DOMINATED BY THE EFFECT OF ANTI-CITRULLINATED PROTEIN ANTIBODIES
T. J. van Wesemael*, M. Verstappen, R. Knevel, A. H. M. van der Helm - van Mil, T. W. J. Huizinga, R. E. M. Toes, D. van der Woude
- P 10.05 RHEUMATOID ARTHRITIS-ASSOCIATED AUTOIMMUNITY DETECTED IN GINGIVAL TISSUE B CELLS: A STUDY OF MALONDIALDEHYDE- AND BACTERIAL CROSS-REACTIVITY ON THE MONOCLONAL LEVEL
C. de Vries*, P. Sahlström, V. Valkovskaia, N. Sherina, B. A. Potempa, T. Yucel-Lindberg, J. S. Potempa, C. Grönwall, K. Lundberg
- P 10.06 THE IMPACT OF MIRNA-SEQ IN MONOCYTES ON IDENTIFICATION OF CIRCULATING MIRNA BIOMARKERS FROM BODY FLUIDS IN EARLY AND ADVANCED RA
M. Ciechomska*, A. Roura, L. Roszkowski, K. Bonek, W. Maslinski
- P 10.07 DISTINCT INTESTINAL MICROBIOTA PHENOTYPES IDENTIFY CHRONIC INFLAMMATORY DISEASES
L. Budzinski*, T. Sempert, G. Kang, R. Riedel, R. Maier, B. Moser, J. Büttner, B. Bochow, A. Schirbel, A. E. Beenken, T. Alexander, S. Bartsch, K. Necke, T. Kallinich, M. Roth, R. Biesen, C. Weidinger, B. Siegmund, L. Lietz, J. Cameron, J. L. Krause, G. A. Heinz, K. Lehmann, U. Hoffmann, M. Mashreghi, A. Radbruch, H. Chang
- P 10.08 ABUNDANT AUTOANTIBODY ISOTYPES IN IDIOPATHIC INFLAMMATORY MYOPATHIES
C. Preger*, A. Notarnicola, C. Hellström, C. Fernandes-Cerqueira, E. Wigren, I. E. Lundberg, P. Jakobsson, H. Persson, S. Gräslund
- P 10.09 CLINICAL PHENOTYPE IN SCLERODERMA PATIENTS BASED ON AUTOIMMUNITY: OUR EXPERIENCE IN A THIRD-LEVEL HOSPITAL
C. Sieiro Santos*, C. Moriano Morales, C. Álvarez Castro, E. Díez Álvarez

- P 10.10 METABOLIC BIOMARKERS UPON ONE-YEAR ANTI-TNF- α THERAPY IN ARTHRITIS PATIENTS
M. Czókolyová*, A. Pusztai, E. Végh, Á. Horváth, A. Szentpéteri, A. Hamar, S. Szamosi, K. Hodosi, A. Domján, S. Szántó, G. Kerekes, I. Seres, M. Harangi, G. Paragh, É. Szekanecz, Z. Szekanecz, G. Szűcs
- P 10.11 NETWORK-BASED APPROACH REVEALS LONG NON-CODING RNAS ASSOCIATED WITH DISEASE ACTIVITY IN LUPUS NEPHRITIS
G. Sentis*, N. Malissovass, D. Nikolopoulos, S. Flouda, A. Pieta, D. T. Boumpas, A. Filia
- P 10.12 BIOMARKERS AND THE METABOLOME IN THE CONTEXT OF END-STAGE KNEE OSTEOARTHRITIS AND OBESITY
P. Schadler, B. Lohberger, B. Thauerer, M. Faschingbauer, W. Kullich, M. H. Stradner, A. Leithner, V. Ritschl, M. Omara, B. Steinecker-Frohnwieser*
- P 10.13 OCCURRENCE OF ANTINUCLEAR AUTOANTIBODIES AND MICROVASCULAR DAMAGE IN PATIENTS WITH SARCOIDOSIS
E. Hysa, F. Cattelan, E. Gotelli, A. Pogna, A. Cere, C. Pizzorni, S. Paolino, R. Campitiello, C. Schenone, S. Soldano, A. Sulli, M. Grosso, E. Barisione, V. Smith, M. Cutolo*
- P 10.14 CLINICAL PERFORMANCE OF CCP2- AND CCP3-BASED ANTI-CCP AUTOANTIBODY TESTS IN EARLY RHEUMATOID ARTHRITIS COHORT
A. Voreck, M. Grundhuber*, R. Aksouh

COVID-19 IN RHEUMATIC DISEASES

ROOM: INNOVATE (1st floor)

Poster Tour Leaders: Joao Fonseca (POR) & Daniela Sieghart (AUT)

- P 12.01 COVID-19 BOOSTER VACCINATION IN NON-SEROCONVERTED IMMUNOSUPPRESSED PATIENTS
D. Sieghart*, D. Mrak, E. Simader, S. Tobudic, H. Radner, P. Mandl, L. Göschl, M. Koblischke, N. Hommer, A. Wagner, L. Hartl, K. Kozibal, P. Hofer, R. Thalhammer, A. Zuckermann, K. Stiansny, T. Perkmann, H. Haslacher, J. H. Aberle, M. Zeitlinger, D. Aletaha, L. X. Heinz, M. Bonelli
- P 12.02 IMMUNE RESPONSES TO MRNA VACCINES AGAINST SARS-COV-2 IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES
C. Sieiro Santos*, C. Moriano Morales, E. Díez Álvarez, S. Calleja Antolín, J. Garcia Ruiz de Morales
- P 12.03 REDUCED TNFA+ CD4 T-CELLS AND GZMB+ CD8 T-CELLS RESPONSES FOLLOWING MRNA VACCINATION AGAINST COVID-19 IN PATIENTS WITH B-CELL DEPLETING THERAPY
C. Sallegger, I. Hodl, B. Dreo, V. Ihm, J. Thiel, M. Stradner, J. Fessler*, CoVvac consortium

- P 12.04 SAFETY AND EFFICACY OF A BOOSTER VACCINATION IN IMMUNOSUPPRESSED PATIENTS AND HEALTHY CONTROLS: AN OPEN LABEL PHASE II STUDY
F. Kartnig*, D. Mrak, E. Simader, H. Radner, P. Mandl, L. Göschl, S. Tobudic, M. Mayer, P. Hofer, T. Deimel, A. Puchner, I. Gessl, T. Hummel, A. Kerschbaumer, R. Thalhammer, S. Winkler, J. S. Smolen, K. Stiasny, T. Perkmann, H. Haslacher, J. H. Aberle, D. Aletaha, L. X. Heinz, D. Sieghart, M. Bonelli
- P 12.05 INFLUENCE OF IMMUNOSUPPRESSIVE BIOLOGIC THERAPY ON RESPONSE TO BOOSTER DOSE OF SARS COV 2 VACCINE IN PATIENTS WITH SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES
C. Trapero Pérez*, C. Ramos Giraldez, R. Martinez Perez, M. Velloso Feijoo, J. Marenco de la Fuente;
- P 12.06 ACUTE PERICARDITIS AND SYSTEMIC AUTOIMMUNE DISEASES
C. Azabal Pérez*, Á. Román Perea, C. Ramos Giráldez, R. Martínez Pérez, M. L. Velloso Feijoo, J. L. Marenco de la Fuente;
- P 12.07 NAILFOLD VIDEOCAPILLAROSCOPY CHANGES OF COVID-19 SURVIVORS
E. Gotelli*, A. Sulli, P. F. Bica, I. Schiavetti, T. Aloè, M. Grosso, E. Barisione, C. Pizzorni, S. Paolino, S. Paolino, V. Smith, M. Cutolo
- P 12.08 IMMUNOGENICITY OF A BOOSTER DOSE OF COVID-19 VACCINATION IN PATIENTS WITH RHEUMATIC DISEASES TREATED WITH IMMUNOMODULATORY DRUGS
J. Wroński*, B. Jaszczyk, L. Roszkowski, K. Bonek, A. Kornatka, M. Plebańczyk, T. Burakowski, B. Lisowska, B. Kwiatkowska, W. Maśliński, M. Wisłowska, M. Massalska, M. Ciechomska, E. Kuca-Warnawin;
- P 12.09 FOURTH SARS-COV-2 VACCINE DOSE IN RITUXIMAB TREATED PATIENTS: AN OPEN LABEL EXTENSION STUDY
D. Mrak*, E. Simader, S. Tobudic, D. Sieghart, M. Koblichke, P. Mandl, B. Kornek, H. Radner, T. Perkmann, H. Haslacher, M. Mayer, P. Hofer, L. Göschl, F. Kartnig, T. Hummel, A. Kerschbaumer, T. Deimel, A. Puchner, I. Gessl, R. Thalhammer, K. Stiasny, S. Winkler, J. S. Smolen, J. H. Aberle, M. Zeitlinger, D. Aletaha, L. X. Heinz, M. Bonelli


POSTERS RELATED TO ORAL PRESENTATIONS

CONGRESS HALL (ground floor)

Oral Presentations are not part of the poster tours
SESSION 1 – TISSUE HOMEOSTASIS

- OP 01 SYNOVIAL TISSUE MACROPHAGE LOSS OF HOMEOSTASIS PREDATES CLINICAL ONSET OF RHEUMATOID ARTHRITIS
M. M. Hanlon*, M. Canavan, N. G. B. Neto, Q. Song, P. Gallagher, R. Mullan, C. Hurson, B. Moran, M. Monaghan, S. Nagpal, D. J. Veale, U. Fearon
- OP 02 FATE AND CONTRIBUTION OF TISSUE-RESIDENT AND BLOOD-DERIVED MACROPHAGES TO HEALTHY AND DISEASED SYNOVIAL NICHES
N. Hannemann, D. Laouteouet, O. Bortolotti, J. Delima, F. Blanchard, F. Apparailly, G. Courties*
- OP 03 SINGLE-CELL CHROMATIN AND TRANSCRIPTOME DYNAMICS OF SYNOVIAL FIBROBLASTS TRANSITIONING FROM HOMEOSTASIS TO PATHOLOGY IN TNF-DRIVEN ARTHRITIS
M. Sakkou*, D. Konstantopoulos, C. Tzaferis, M. D. Lavigne, A. Liakos, M. A. Dimopoulos, P. P. Sfikakis, M. Fousteri, G. Kollias, M. Armaka

SESSION 2 – GENES AND BIOMARKERS

- OP 04 POLYCLONAL AND MONOCLONAL ANTI-CITRULLINATED AUTOANTIBODY RESPONSE INDUCED BY COVID-19 DISEASE BUT NOT BY SARS-COV-2 VACCINATION IN RHEUMATOID ARTHRITIS PATIENTS
M. Jennings, L. Frommert, A. Arumahandi de Silva, F. Albach, R. Biesen, G. Burmester, T. Kallinich, L. Sander, K. Skriner*
- OP 05 COMPARISON BETWEEN MIRNA BIOMARKER EXPRESSION AND ENDOTHELIAL CELL PATHOGENICITY IN RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS
O. Tynan*, C. Cunningham, M. M. Hanlon, A. Floudas, M. Canavan, U. Fearon, D. J. Veale
- OP 06 SCREENING FOR CIRCULATING MIRNAS CHARACTERIZING PATIENTS WITH DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS
J. Baloun*, A. Pekáčová, H. Mann, J. Vencovský, K. Pavelka, L. Šenolt

SESSION 3 – EPIGENETICS

- OP 07 MIRNA PROFILING OF PERIPHERAL BLOOD MONONUCLEAR CELLS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS
A. Pekacova*, J. Baloun, K. Bubova, M. Gregova, S. Forejtova, J. Horinkova, M. Husakova, M. Tomcik, J. Gatterova, J. Vencovsky, K. Pavelka, L. Senolt
- OP 08 ANATOMICAL TRANSCRIPTIONAL DIVERSITY OF HOMEODOMAIN TRANSCRIPTION FACTORS TRANSLATES INTO JOINT-SPECIFIC SYNOVIAL FIBROBLAST PHENOTYPES
M. Mirrahimi*, K. Klein, M. Frank-Bertoncelj, M. Houtman, O. Distler, C. Ospelt
- OP 09 T CELL PRIMING OF A SPECIFIC ACTIVATION STATE IN CD34POS SYNOVIAL TISSUE FIBROBLASTS THAT DRIVES T CELL RECRUITMENT TO THE JOINT
S. Kemble*, C. B. Mahony, C. G. Smith, P. Reis Nisa, L. Marsh, A. P. Croft

SESSION 4 – INNATE IMMUNE CELLS

- OP 10 EOSINOPHILS CONTROL ARTHRITIS-INDUCED BONE LOSS BY INHIBITING OSTEOCLASTS THROUGH EOSINOPHIL PEROXIDASE
D. Andreev*, K. Kachler, M. Liu, B. Krishnacoumar, G. Krönke, D. Vöhringer, G. Schett, A. Bozec
- OP 11 ORIGIN AND ROLE OF MACROPHAGE SUBSETS IN THE PATHOPHYSIOLOGY OF OSTEOARTHRITIS
D. Laouteouet*, N. Hannemann, O. Bortolotti, M. Chambon, A. Blömeke-Eiben, J. Delima, F. Blanchard, F. Apparailly, G. Courties
- OP 12 MALADAPTIVE ACTIVATION OF TRAINED IMMUNITY IN THE PATHOGENESIS AND TREATMENT OF GIANT CELL ARTERITIS
E. Cantoni, I. Merelli, D. Stefanoni, A. Tomelleri, C. Campochiaro, A. Ziogas, J. Domínguez-Andrés, B. Vergani, B. Leone, B. Leone, M. Matucci-Cerinic, A. D'Alessandro, L. Dagna, L. Joosten, M. Netea, R. Molteni, G. Cavalli*

SESSION 5 – REGENERATIVE MEDICINE

- OP 13 NOS INHIBITION REVERSES TLR2-INDUCED CHONDROCYTE DYSFUNCTION AND ATTENUATES AGE-RELATED OSTEOARTHRITIS
P. Shen*, S. Serve, P. Wu, M. Fuchs, T. Maleitzke, M. Reisener, M. Dзамukova, T. Brunner, N. Durán-Hernández, Y. Li, F. Heinrich, P. Durek, G. Katsoula, E. Zeggini, T. Winkler, M. Mashreghi, M. Pumberger, C. Perka, M. Löhning
- OP 14 SYNOVIAL FIBROBLASTS IN OSTEOARTHRITIS ARE MARKED BY PATHOLOGICALLY OVEREXPRESSED PYRUVATE DEHYDROGENASE KINASES
A. Damerou*, M. Kirchner, M. Pfeiffenberger, L. Ehlers, D. Do Nguyen, P. Mertins, B. Bartek, T. Maleitzke, Y. Palmowski, S. Hardt, T. Winkler, F. Buttgereit, T. Gaber
- OP 15 ROLE OF NRG/ERBB SIGNALING AXIS IN CARTILAGE REGENERATION IN ZEBRAFISH
D. Sapède, S. Bahraoui, L. Abou Nassif, A. Barthelaix, C. Jorgensen, F. Djouad*

SESSION 6 – B CELLS AND T CELLS

- OP 16 PERIPHERAL MONONUCLEAR CELLS OF RA PATIENTS INITIATE ARTHRITIS IN NSG-DR4 MICE
J. Rupp*, J. Fessler, S. Hayer, B. Dreö, A. Lackner, P. Fasching, W. Helmberg, P. Schlenke, J. Thiel, G. Steiner, C. M. Weyand, M. H. Stradner
- OP 17 IRF1-MEDIATED ATR DNA DAMAGE RESPONSE SIGNALING DRIVES B CELL HYPERREACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS
T. Manolakou*, D. Nikolopoulos, D. Gkikas, A. Filia, M. Samiotaki, A. Fanouriakis, A. Banos, T. Alissafi, P. Verginis, D. Boumpas
- OP 18 IGM MYELOPEROXIDASE (MPO)-SPECIFIC B CELL EXPANSION IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS
C. M. Wortel, R. van de Wetering, H. van Dooren, E. M. Stork, A. Bakker, A. Brehler, T. Kissel, S. Reijm, G. Stoeken-Rijsbergen, K. van Schie, A. Rutgers, L. A. Trouw, T. W. J. Huizinga, O. Teng, C. van Kooten, P. Heeringa, R. E. M. Toes, H. U. Scherer*

**SESSION 7 – ORGAN AND TISSUE INFLAMMATION**

- OP 18 MIR-221/222 REGULATE SYNOVIAL FIBROBLAST EXPANSION AND PATHOGENESIS OF TNF-MEDIATED ARTHRITIS
F. Roumelioti*, C. Tzaferis, D. Konstantopoulos, D. Papadopoulou, M. Sakkou, A. Liakos, N. Karagianni, M. Denis, M. Fousteri, M. Armaka, G. Kollias
- OP 20 INSIDE THE JOINT OF INFLAMMATORY ARTHRITIS PATIENTS: HANDLING AND PROCESSING OF SYNOVIAL TISSUE BIOPSIES FOR HIGH THROUGHPUT ANALYSIS
A. Floudas, A. Gorman, N. Neto, M. G. Monaghan, Z. Elliott, D. J. Veale, U. Fearon, V. Marzaioli*
- OP 21 RESET OF INFLAMMATORY PRIMING OF JOINT TISSUE AND REDUCTION OF THE SEVERITY OF ARTHRITIS FLARES BY BROMODOMAIN INHIBITION
J. Friscic, M. Houtman, M. Böttcher, V. Trajkovic, K. Klein, D. Mougiakakos, C. Ospelt, G. Schett, M. Hoffmann*

SESSION 8 – JOINT DEGENERATION AND REPAIR

- OP 22 THE PHYSIOLOGICAL HYPOXIC ENVIRONMENT OF ARTICULAR CARTILAGE TRIGGERS DOT1L EXPRESSION TO PROTECT AGAINST OSTEOARTHRITIS
A. De Roover*, A. Escribano, F. Cornelis, C. Cherifi, L. Casas-Fraile, A. Sermon, F. Cailotto, R. Lories, S. Monteagudo
- OP 23 TARGETING CARTILAGE DAMAGE AS A TRIGGER OF MESENCHYMAL ACTIVATION IN DESTRUCTIVE JOINT DISEASES
S. Bödecker*, L. Tykocinski, A. Krause, F. Bischoff, T. Pap, A. Korb-Pap, J. Sherwood
- OP 24 THE AVAILABILITY OF SERINE IS CRITICAL FOR OSTEOCLAST DIFFERENTIATION
M. Kieler*, M. Hofmann, G. Heller, G. Schabbauer, S. Blüml

SESSION 9 – PRECISION MEDICINE AND NOVEL TARGETS

- OP 25 DIGITAL SPATIAL PROFILING REVEALS DISTINCT SYNOVIAL TISSUE MACROPHAGE TRANSCRIPTOMIC SIGNATURE OF SUSTAINED REMISSION IN RHEUMATOID ARTHRITIS PATIENTS AT RISK OF DISEASE FLARE AFTER TREATMENT CESSATION
S. Perniola, B. Tulusso, A. Elmesmari, M. Gessi, C. Di Mario, M. Gigante, L. Petricca, D. Bruno, D. Somma, A. Paglionico, V. Varriano, L. Bui, M. D'agostino, M. Kurowska-Stolarska, E. Gremese, S. Alivernini*
- OP 26 METABOLIC IMBALANCE OF SYNOVIAL FIBROBLASTS IN INDIVIDUALS AT RISK OF RHEUMATOID ARTHRITIS
T. A. de Jong*, J. F. Semmelink, S. W. Denis, R. H. L. Houtkooper, L. G. M. van Baarsen
- OP 27 PROOF-OF-CONCEPT OF FIBROBLAST-TARGETED PHOTODYNAMIC THERAPY IN HUMAN 3D SCLERODERMA SKIN MODEL AND BLEOMYCIN-INDUCED SKIN FIBROSIS IN MICE
D. N. Dorst*, A. P. M. van Caam, E. L. Vitters, B. Walgreen, M. M. A. Helsen, C. Klein, S. Gudi, T. Wubs, J. Kumari, P. Blyszczuk, M. C. Vonk, P. M. van der Kraan, M. I. Koenders

Thanks to the generous support of EULAR, these young researchers were awarded travel bursaries to facilitate participation at the 41st European Workshop for Rheumatology Research

Daria Andreev (GER)
 Brianne Barker (IRL)
 Sarah Bödecker (GER)
 Dario Bruno (IT)
 Yangrong Cai (GER)
 Monika Czókolyová (HUN)
 Astrid De Roover (BEL)
 Charlotte de Vries (SWE)
 Charlotte Donaubauer (GER)
 Daphne Dorst (NL)
 Barbara Dreo (AUT)
 Kerstin Dürholz (GER)
 Jean Escal (FR)
 Bianca Fioretto (IT)
 Laure Gallay (FR)
 Emanuele Gotelli (IT)
 Panagiota Goutakoli (GR)
 Attila Hamar (HUN)
 Megan Hanlon (IRL)
 Amela Hukara (CH)
 Amro Hussein (CH)
 Eszter Kaposztas (HUN)
 Ravi Kumar (SWE)
 Mégane Lacaud (FR)
 Christopher Mahony (UK)
 Theodora Manolakou (GR)
 Lucy-Jane Marsh (UK)
 Dimitria Nikoleri (GR)
 Patricia Nisa (UK)
 Dimitra Papadopoulou (GR)
 Sane Reijm (NL)
 Janine Rupp (AUT)
 Georgios Sentis (GR)
 Vikar Simon (HUN)
 Maarten Steinz (NL)
 Catarina Tomé (POR)
 Issam Tout (FR)
 Orla Tynan (IRL)
 Tineke van Wesemael (NL)
 Eugenie Werbenko (GER)

eular

fighting rheumatic & musculoskeletal
diseases together



Thursday, May 5 (13:30 - 15:30)

European Consensus Finding Study Group on Laboratory Investigation in Rheumatology (ECFSG)

Room Texas Eagle, Conference Level (1st floor)

Chair: Johan Rönnelid

13:30	Welcome	<i>Johan Rönnelid</i>
13:35	Reflections on the origins of the European Consensus Finding Study Group	<i>Josef Smolen</i>
13:50	Presentation and discussion on this years' serum round	<i>Charlotta Dahle</i>
14:50	IVDR requirements for lab-developed tests by May 2022 and how to prepare as a lab	<i>Dörte Hamann</i>
15:20	Activities during the coming year	<i>Johan Rönnelid</i>
15:30	Closure	

Gene & Cell Therapy Study Group (GCTSG)

Room Orient Express, Conference Level (1st floor)

Chairs: Farida Djouad and Christian Jorgensen

13:30	SEN-OA introduction	<i>Danièle Noel</i>
13:40	Senescence markers in murine and human OA: histological analyses and cellular models OA	<i>WP2 - Claire Vinatier Xavier Houard</i>
14:00	Impact of senescence on caudal fin regeneration in zebrafish	<i>WP3 - Farida Djouad</i>
14:20	Case Studies on Emerging Targets in Joint Aging and OA	<i>WP3 - Beatriz Carames</i>
14:40	Therapeutic function of senescence-induced MSC derived extracellular vesicles	<i>WP3 - Danièle Noël</i>
15:00	Targeting Senescence to Identify Novel Therapeutics for OA	<i>WP4 - Beatriz Carames</i>
15:20	end of the Study group	
15:30-15:45	Round table with the SAB (for SEN-OA consortium members only)	

Study Group on Osteoarthritis (SGOA)

Room Trans Siberian, Conference Level (1st floor)

Chair: Joanna Sherwood

The session is kept as an informal opportunity to get together with those who are interested in OA research.



abbvie

We leverage deep scientific expertise to develop next-generation biologics and small molecules in rheumatology, dermatology and gastroenterology.

AbbVie medicines in immunology currently treat +1 million patients in 15 indications worldwide.

TNF: human monoclonal antibody for treatment of 15 indications.

Interleukine: IL-23 antibody for treatment of psoriasis. Clinical studies in further indications.

JAKi: Januskinase-inhibitor for treatment of rheumatoid arthritis, psoriatic arthritis und ankylosing spondylitis and atopic dermatitis. Clinical studies in further indications.

More information:
abbvie.at
abbvie.com

Innovative treatments in
Immunology

**People. Passion.
Possibilities.®**

WE WOULD LIKE TO THANK OUR SPONSORS

Platinum Sponsor



Gold Sponsor




Silver Sponsors




Bronze Sponsors






Additional Sponsors







Special Thanks



Österreichische Gesellschaft für
Rheumatologie & Rehabilitation



LUDWIG
BOLTZMANN
GESELLSCHAFT



Lilly unites caring with discovery to create medicines that make life better for people around the world.

We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.

To learn more, visit [Lilly.com](https://www.lilly.com)



At **Janssen**, we're creating a future where disease is a thing of the past. We're fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at www.janssen.com.

Follow us at www.twitter.com/JanssenGlobal.

Janssen Austria is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

AT_ CP-310361_11April2022

abbvie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.

For more information about AbbVie, please visit us at www.abbvie.com.

Follow @abbvie on [Twitter](#), [Facebook](#), [Instagram](#), [YouTube](#) and [LinkedIn](#).


Galápagos

Galapagos is developing small molecule drugs with novel mechanisms of action for the treatment of various diseases, many of which are showing promising results in currently ongoing studies. Founded in 1999, the biopharma company's pipeline includes clinical programs in inflammation, fibrosis and other indications. Galapagos has also had a subsidiary in Austria since 2021.


For the bigger picture, visit glpg.com



GROUND LEVEL



1ST LEVEL



Our commitment to inflammation

In our core therapeutic area of chronic inflammatory diseases, a new era has begun for us.

With a strong focus on research, we aim to address large areas of unmet medical needs, improve people's lives, and make a lasting positive contribution to society.



23 years of ground-breaking research and development



Established in Europe



45+ drug targets discovered



45 % of employees work in R&D



70 % of operating expenses are in R&D*



at.glp.com



Your expertise and our shared conversations are inspiration for our Galapagos services. Let's work together to make therapy management in RA even more suitable for the daily needs of patients."

Mag. (FH) Mariella Corrieri
Product Management
Rheumatology



The therapy of rheumatoid arthritis is not just an important research topic for us, but a matter of the heart. All our activities aim to improve the lives of those suffering from rheumatoid arthritis."

Mag. Dr. Katja Pachner
Medical Affairs
Rheumatology

* Values as per 31.12.2021

Galapagos Biopharma Austria GmbH
Herrengasse 1-3, A-1010 Wien

AT-RA-NA-202204-00001; Erstellt: April 2022

Galápagos

Pioneering for patients



MEDICAL UNIVERSITY
OF VIENNA

eular

fighting rheumatic & musculoskeletal
diseases together